GC
RGNX icon

GMT Capital’s Regenxbio RGNX Stock Holding History

GMT Capital’s Portfolio RGNX Stock Details RGNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-483,626
Closed -$16.1M – 116
2017
Q4 		$16.1M Sell
483,626
-414,441
-46% -$12.5M 0.33% 68
2017
Q3 		$29.6M Buy
898,067
+288,367
+47% +$6.49M 0.59% 49
2017
Q2 		$12.3M Buy
609,700
+558,300
+1,086% +$10.8M 0.27% 74
2017
Q1 		$992K Buy
+51,400
New +$991K 0.02% 103

Other funds holding RGNX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

GMT Capital's RGNX Position: Q1 2018 in Review

GMT Capital sold out of Regenxbio (RGNX) in Q1 2018, closing a stake of 483,626 shares — an estimated $16.1M sold.

GMT Capital first reported a position in RGNX in Q1 2017 and held it in 4 quarters. The position peaked at $29.6M in Q3 2017. 120 funds tracked by Wall St. Rank hold RGNX as of Q1 2018.

  • GMT Capital reported no remaining Regenxbio position as of Q1 2018 after selling out during the quarter.
  • GMT Capital sold 483,626 Regenxbio shares in Q1 2018, an estimated $16.1M.
  • GMT Capital first reported a position in Regenxbio in Q1 2017 and held it in 4 quarters.
  • GMT Capital's Regenxbio position peaked at $29.6M in Q3 2017.
  • 120 funds tracked by Wall St. Rank held Regenxbio as of Q1 2018.

Based on GMT Capital's 13F filing for Q1 2018, filed 15 May 2018.